A new horizon for the old antibacterial drug clofoctol

被引：13

作者：

Bailly, Christian ^{[1
]}

Vergoten, Gerard ^{[2
]}

机构：

[1] OncoWitan, F-59290 Lille, Wasquehal, France

[2] Univ Lille, Inst Chim Pharmaceut Albert Lespagnol ICPAL, Fac Pharm, Inserm,INFINITE,U1286, 3 Rue Prof Laguesse,BP-83, F-59006 Lille, France

来源：

DRUG DISCOVERY TODAY | 2021年 / 26卷 / 05期

关键词：

UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; FORCE-FIELD; CANCER; PERK; INHIBITOR; GROWTH; CDC7; ACTIVATION; EXPRESSION;

D O I：

10.1016/j.drudis.2021.02.004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The synthetic antibacterial drug clofoctol (CFT) has long been used to treat respiratory tract infections in Europe. In recent years, the drug was found to target two biologically important proteins, the Cdc7/Dbf4 protein kinase complex and the mRNA-binding protein cold shock domain containing E1 (CSDE1), also known as upstream-of-N-Ras protein (UNR). These interactions are at the origin of the antitumor activity of CFT, recently evidenced in prostate cancer and neuroglioma. Drug-protein binding models provide a structural basis to guide the design of more potent anticancer compounds. A renewed interest in CFT can be anticipated for the treatment of cancers, and possibly Coronavirus 2019 (COVID-19).

引用

页码：1302 / 1310

页数：9

共 73 条

[1]

ALESSANDRI MG, 1986, DRUG EXP CLIN RES, V12, P343

[2]

Amoros M, AMOROS M, Patent No. EP0521906A1

[3] Regulation of the expression and activity of Unr in mammalian cells [J].